Literature DB >> 6601332

Plasmapheresis in clinical medicine.

C Linker.   

Abstract

Large-volume plasma exchange can now be rapidly and safely done using cell separator technology. Significant depletion of immunoglobulins and immune complexes can be achieved by repeated intensive plasmapheresis, but sustained depletion of these constituents requires concomitant immunosuppressive therapy. Plasmapheresis appears to work in some disorders by removing pathogenic antibodies, but other mechanisms of action have been postulated. It is the treatment of choice for thrombotic thrombocytopenic purpura and for the hyperviscosity syndrome due to macroglobulinemia. Apheresis can be useful in the treatment of many other disorders, most notably myasthenia gravis, glomerulonephritis associated with hemoptysis (Goodpasture's syndrome), refractory systemic lupus erythematosus, cryoglobulinemia and immune cytopenic disorders.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601332      PMCID: PMC1010632     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  31 in total

Review 1.  Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura.

Authors:  R M Bukowski; J S Hewlett; J W Harris; G C Hoffman; J D Battle; E Silverblatt; I Y Yang
Journal:  Semin Hematol       Date:  1976-07       Impact factor: 3.851

2.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.

Authors:  P C Dau; J M Lindstrom; C K Cassel; E H Denys; E E Shev; L E Spitler
Journal:  N Engl J Med       Date:  1977-11-24       Impact factor: 91.245

3.  Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.

Authors:  R M Bukowski; J W King; J S Hewlett
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

4.  Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus.

Authors:  M M Frank; M I Hamburger; T J Lawley; R P Kimberly; P H Plotz
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

5.  A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis.

Authors:  D Wallace; D Goldfinger; C Lowe; S Nichols; J Weiner; M Brachman; J R Klinenberg
Journal:  N Engl J Med       Date:  1982-06-10       Impact factor: 91.245

6.  Plasmapheresis in the management of acute systemic lupus erythematosus?

Authors:  J V Jones; R H Cumming; R C Bucknall; C M Asplin
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

7.  Immunosuppression and plasma-exchange in the treatment of Goodpasture's syndrome.

Authors:  C M Lockwood; A J Rees; T A Pearson; D J Evans; D K Peters; C B Wilson
Journal:  Lancet       Date:  1976-04-03       Impact factor: 79.321

8.  Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis.

Authors:  C M Lockwood; A J Pinching; P Sweny; A J Rees; B Pussell; J Uff; D K Peters
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

9.  Plasma exchange in the treatment of fulminant idiopathic (autoimmune) thrombocytopenic purpura.

Authors:  R F Branda; D Y Tate; J J McCullough; H S Jacob
Journal:  Lancet       Date:  1978-04-01       Impact factor: 79.321

10.  Regulation of antibody formation by serum antibody. I. Removal of specific antibody by means of immunoadsorption.

Authors:  M W Graf; J W Uhr
Journal:  J Exp Med       Date:  1969-11-01       Impact factor: 14.307

View more
  3 in total

1.  Pemphigus.

Authors: 
Journal:  West J Med       Date:  1983-05

2.  Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness.

Authors:  Matthias Klingele; Carina Allmendinger; Solmaz Thieme; Lea Baerens; Danilo Fliser; Bürmann Jan
Journal:  Sci Rep       Date:  2020-05-13       Impact factor: 4.379

3.  Total Plasma Exchange in Neuromuscular Junction Disorders-A Single-Center, Retrospective Analysis of the Efficacy, Safety and Potential Diagnostic Properties in Doubtful Diagnosis.

Authors:  Andreas Totzeck; Michael Jahn; Benjamin Stolte; Andreas Thimm; Christoph Kleinschnitz; Tim Hagenacker
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.